Scrutiny Mounts Over BMJ Stem Cell Study After Data Discrepancies Emerge
A high-profile study published in The BMJ in late October 2025, which claimed that stem cell therapy could reduce the risk of heart failure after a heart attack, is now under intense scrutiny after independent researchers uncovered significant inconsistencies in the data. The study, based on the PREVENT-TAHA8 phase III clinical trial conducted in Shiraz, Iran, reported that patients receiving stem cell therapy had better outcomes than those receiving standard care. The findings were widely publicized, with The BMJ issuing a press release and several news outlets highlighting the results as a major breakthrough in cardiac care.
Alleged Data Mismatches and Methodological Concerns
Within days of publication, experts including Dorothy Bishop, professor of developmental neuropsychology at Oxford University, raised concerns on the scientific discussion platform PubPeer. Bishop pointed out a “complete mismatch” between the study’s eligibility criteria and the published dataset: while the trial protocol stated that only patients under 65 years old were enrolled, the dataset included 127 patients over that age. Further analysis by other researchers revealed additional red flags, including a repeating pattern in the data and an unusually high proportion of patient weights reported as whole numbers, especially multiples of five kilograms. These patterns suggest possible data fabrication or manipulation, according to experts.
Another discrepancy emerged between the number of patients reported in the study (420) and those listed in the trial’s official registration (360). The BMJ’s peer review records show that the journal had “serious concerns regarding the reporting and data sharing” during the review process, and the authors only shared the full dataset after the final review. The BMJ’s head of media relations acknowledged that the journal is taking the concerns seriously and is reviewing the situation.
Broader Context: Stem Cell Research and Research Integrity
This incident highlights ongoing challenges in stem cell research, a field that has faced repeated controversies over data integrity. In 2018, more than 30 papers from the lab of Piero Anversa were retracted due to falsified data, and the National Institutes of Health continues to fund research in this area while emphasizing the need for rigorous oversight. A recent systematic analysis of retracted publications in stem cell research found that data and image flaws were the most common reasons for retraction, and that retracted papers often continue to be cited, sometimes even more frequently after retraction. This underscores the importance of robust surveillance mechanisms and standardized protocols to ensure research integrity.
Public Health Implications
The credibility of clinical research is critical for patient care and public health policy. Flawed studies can mislead clinicians, waste resources, and erode public trust in science. The BMJ’s swift response to the concerns is a positive step, but it also highlights the need for greater transparency and accountability in the publication process. Researchers and journals must prioritize data sharing, rigorous peer review, and prompt investigation of allegations of misconduct to protect the integrity of medical science.
For patients and healthcare providers, this episode serves as a reminder to critically evaluate new treatments and to rely on evidence from well-conducted, transparent studies. The field of stem cell therapy holds promise, but it must be advanced through rigorous, ethical research that withstands scrutiny. For more on the latest developments in stem cell research and clinical trials, read more on Globally Pulse Health.
